| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | European Journal of Cancer | 2009 | 16.1K |
| Cancer statistics, 2009 | Ca-A Cancer Journal for Clinicians | 2009 | 8.6K |
| Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Lancet Oncology, The | 2009 | 5.1K |
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Lancet Oncology, The | 2009 | 4.2K |
| Final version of 2009 AJCC melanoma staging and classification | Journal of Clinical Oncology | 2009 | 3.5K |
| STATs in cancer inflammation and immunity: a leading role for STAT3 | Nature Reviews Cancer | 2009 | 2.9K |
| A flexible and accurate genotype imputation method for the next generation of genome-wide association studies | PLoS Genetics | 2009 | 2.9K |
| Supervised risk predictor of breast cancer based on intrinsic subtypes | Journal of Clinical Oncology | 2009 | 2.9K |
| Microenvironmental regulation of metastasis | Nature Reviews Cancer | 2009 | 2.7K |
| Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits | Nature Reviews Cancer | 2009 | 2.6K |
| Cell cycle, CDKs and cancer: a changing paradigm | Nature Reviews Cancer | 2009 | 2.5K |
| Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria | Clinical Cancer Research | 2009 | 2.4K |
| Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients | Radiotherapy and Oncology | 2009 | 2.1K |
| Targeting cancer with small molecule kinase inhibitors | Nature Reviews Cancer | 2009 | 2K |
| Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study | Lancet Oncology, The | 2009 | 2K |
| Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis | Cancer Cell | 2009 | 1.9K |
| Metastasis: from dissemination to organ-specific colonization | Nature Reviews Cancer | 2009 | 1.9K |
| Targeting PI3K signalling in cancer: opportunities, challenges and limitations | Nature Reviews Cancer | 2009 | 1.9K |
| Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability | Carcinogenesis | 2009 | 1.9K |
| Global epidemiology of oral and oropharyngeal cancer | Oral Oncology | 2009 | 1.9K |
| Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma | Journal of Clinical Oncology | 2009 | 1.9K |
| Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN | Cancer Cell | 2009 | 1.8K |
| p21 in cancer: intricate networks and multiple activities | Nature Reviews Cancer | 2009 | 1.8K |
| Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma | Journal of Clinical Oncology | 2009 | 1.7K |
| Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group | Journal of Clinical Oncology | 2009 | 1.7K |
